A subject and investigator blinded, randomized, placebo controlled,repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis
Grant
Overview
abstract
-
The purpose of this proof-of-concept study is to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis. To assess the efficacy of CMK389 in subjects with chronic pulmonary sarcoidosis by looking at the change from baseline to end-of-treatment (16 weeks of treatment) in forced vital capacity (FVC).
date/time interval
awarded by